0
Editor's Correspondence |

Hypercoagulable Disorders

Bernard Goichot, MD, PhD; Anne-Elisabeth Perrin, MD
Arch Intern Med. 2002;162(15):1785-1787. doi:.
Text Size: A A A
Published online

Extract

Thomas1 has proposed in the November 12, 2001, issue of the ARCHIVES a practical review of hypercoagulability syndromes. We would like to comment on several points. Indications of thrombophilia screening remain a matter of debate and we regret that this point was not discussed in the article. Limiting this debate to its financial aspect, as it could be interpreted from Table 2, which gives the cost of different assays, is not correct in our opinion. For instance, detecting an increase of factor VIII ($90) today has no recognized therapeutic implications, whereas elevated homocysteine concentration ($324) can lead to safe, inexpensive, and probably effective vitamin supplementation. Which screening to use and for which patients is a very difficult problem that has been discussed elsewhere and that must not be overlooked.2 In the summary, Thomas stated that hypercoagulability syndrome can be "correctly diagnosed" in approximately 80% to 90% of patients. This appears to be a rather presumptuous affirmation. If this means that extensive workup will lead to identification of coagulation abnormalities in this percentage of patients, this is probably true, even if perhaps a little optimistic. But as emphasized by Thomas himself, patients with antithrombin deficiency (which is the genetic thrombophilia associated with the higher relative risk of thrombosis) may have no problem until they undergo surgery or any other risk-associated situation and, in fact, the majority of carriers of antithrombin deficiency will never have thrombosis. We should probably in most cases leave the concept of thrombophilia/hypercoagulability as an explicative factor, to think in terms of risk factor. We do not "explain" a myocardial infarction by hypercholesterolemia; it is "just" an important risk factor. This way of thinking will perhaps facilitate therapeutic decisions. Thus, in the Figure that summarizes the recommended approach to treatment of hypercoagulability, Thomas suggests that people having more than 1 coagulation abnormality should be candidates for "lifelong" (another presumptuous expression in our opinion) anticoagulation after 1 episode of thrombosis, whereas people with recurrent thrombosis but no defect identified should be treated with "standard" therapy. We think this doesn't really reflect the view of the author but the Figure can be misleading and should be corrected. For instance, a 20-year-old man who has severe pulmonary embolism in the absence of favoring conditions (eg, surgery, prolonged immobilization) has indeed thrombophilia, whatever the result of hypercoagulability workup, and should receive long-term anticoagulation. Last, the Figure suggests that family studies may be prothrombin promoter gene: this attitude is extremely questionable because of the absence of therapeutic consequences in the family.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();